Intra-aortic balloon counterpulsation did not significantly reduce in-hospital and 30-day mortality compared to conventional treatment in patients with acute myocardial infarction.
Meta-Analysis (n=2,538)
Yes
Does intra-aortic balloon counterpulsation (IABP) reduce mortality in patients with acute myocardial infarction?
While routine IABP does not reduce overall mortality in AMI patients, its use prior to PCI may be associated with reduced short- and medium-term mortality.
Effect estimate: OR 0.85 (95% CI 0.67-1.08)
Absolute Event Rate: 16.2% vs 18.1%
p-value: p=0.19
BACKGROUND: This study aimed to evaluate the impact of intra-aortic balloon counterpulsation (IABP) on the prognosis of patients with acute myocardial infarction (AMI). METHODS: We identified and included in this study AMI cases treated with IABP from January 1970 to May 2014. For statistical analysis, we utilized RevMan 5.0 software. RESULTS: Fourteen RCTs with a total population of 2538 were included in this study. The in-hospital and 30-day mortality rate in the IABP group was not significantly lower than those in the non-IABP group. Subgroup analysis according to the type of revascularization, OR values of TT subgroup, PCI subgroup, and CABG subgroup were 0.64 (95% CI 0.25-1.61, p = 0.34), 0.85 (95% CI 0.65-1.11, p = 0.23) and 0.46 (95% CI 0.13-1.63, p = 0.23). And OR values of AMI patients in the before and after PCI subgroup were 0.43 (95% CI 0.21-0.91, p = 0.03) and 1.36 (95% CI 0.76-2.41, p = 0.30). The 6-month mortality in the IABP group was not significantly lower than that in the non-IABP group. And OR values of 6-month mortalities of the before and after PCI subgroup were 0.47 (95% CI 0.26-0.86, p = 0.01) and 1.40 (95% CI 0.57-3.45, p = 0.47). CONCLUSIONS: IABP did not reduce the in-hospital and 30-day mortality of AMI patients, and did not reduce the 6-month mortality. But IABP used in AMI patients before PCI was associated not only with reduced in-hospital and 30-day mortality, but also reduced 6-month mortality.
Gao et al. (Wed,) conducted a meta-analysis in Acute myocardial infarction (n=2,538). Intra-aortic balloon counterpulsation (IABP) vs. Conventional standard treatment (non-IABP) was evaluated on In-hospital and 30-day mortality (OR 0.85, 95% CI 0.67-1.08, p=0.19). Intra-aortic balloon counterpulsation did not significantly reduce in-hospital and 30-day mortality compared to conventional treatment in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: